JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB137132

Anti-PD1 antibody [EPR4877(2)]

  • BOND RX™ Validated
  • 20ul selling size
  • RabMAb
  • Recombinant
  • What is this?

5

(5 Reviews)

|

(138 Publications)

Anti-PD1 antibody [EPR4877(2)] (ab137132) is a rabbit monoclonal antibody detecting PD1 in IHC-P. Suitable for Human.

- Biophysical QC for unrivalled batch-batch consistency
- Over 100 publications

View Alternative Names

CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, hPD-1

9 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)
  • IHC-P

AbReview80034****

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of formaldehyde fixed human tonsil staining with ab137132 at 1/500 dilution. Secondary antibody used was BOND Refine Detection. The sample was incubated with the primary antibody for 30 minutes. Antigen retrieval method was heat mediated BOND ER2

This image is courtesy of an anonymous Abreview

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)
  • IHC-P

PubMed

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)

Formalin-fixed paraffin-embedded early RA synovial biopsies were cut into 5 μM sections and mounted on Fisherbrand Superfrost Plus Slides. The sections were stained with anti-CD3 and anti-PD1 (ab137132, Abcam) antibodies. The markers were visualized with 3,3'-diaminobenzidine and the relative expression of each marker was noted. CD3 and PD1 staining was reported as CD3+% or PD1+% cells within a total magnification of 100x across the entire biopsy section.

Guo Y et al. Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS One 13:e0192704 (2018). Fig 4.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)

Immunohistochemical analysis using ab137132 (unpurified) showing negative staining in human skeletal muscle tissue.

Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil tissue labeling PD1 with ab137132 at a dilution of 1/500. Heat mediated antigen retrieval was performed using EDTA antigen retrieval solution, and microwave treatment for 20 min at 20% power. Anti-Rabbit HRP polymer was used as secondary antibody. Opal tyramide amplification was performed using Opal 540 fluorophore. Counterstained with DAPI stain.

Image scanned with Vectra 3.0 and analyzed via Inform software.

This image was courteously provided by Dr. Houssein Abdul Sater, Georgia Cancer Center.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)

Immunohistochemical analysis using ab137132 (unpurified version) showing negative staining in normal human brain tissue.

Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil tissue labeling PD1 with purified ab137132 at 1/500. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. ab97051, an HRP-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/500).

Negative control : Secondary antibody only using PBS instead of primary antibody. Counterstained with hematoxylin.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil tissue labeling PD1 with unpurified ab137132 at a dilution of 1/250.

Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human T-cell lymphoma tissue labeling PD1 with unpurified ab137132 at a dilution of 1/250.

Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)
  • IHC-P

Lab

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR4877(2)] (AB137132)

Tissue Microarrays stained for "Anti-PD1 antibody [EPR4877(2)]" using "ab137132"in immunohistochemical analysis. This table provides a detailed overview of positive (tick mark) and negative (cross mark) staining per sample type tested. The sections were pre-treated using Heat mediated antigen retrieval using Bond™ Epitope Retrieval Solution 2 (pH 9.0) for 20 minutes. The sections were incubated with ab137132 for 30 mins at room temperature followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). The immunostaining was performed on a Leica Biosystems BOND® RX instrument.

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR4877(2)

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

Alternative Products

Primary Antibodies

AB183641

Anti-PD1 antibody

Western blot - Anti-PD1 antibody (AB183641)

  • 0
  • 0
Primary Antibodies

AB216037

Anti-PD1 antibody [PDCD1/922]

  • 0
  • 0
Primary Antibodies

AB218930

Anti-PD1 antibody [PDCD1/1410R] - BSA and Azide free

Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [PDCD1/1410R] - BSA and Azide free (AB218930)

  • 0
  • 0
Primary Antibodies

AB269805

Anti-PD1 antibody [SPM597] - BSA and Azide free

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [SPM597] - BSA and Azide free (AB269805)

  • 0
  • 0
Primary Antibodies

AB218474

Anti-PD1 antibody [SPM597]

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [SPM597] (AB218474)

  • 0
  • 0
Primary Antibodies

AB215847

Anti-PD1 antibody [PDCD1/922] - BSA and Azide free

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [PDCD1/922] - BSA and Azide free (AB215847)

  • 0
  • 0
Primary Antibodies

AB223562

Anti-PD1 antibody [EH12.2H7]

Flow Cytometry - Anti-PD1 antibody [EH12.2H7] (AB223562)

  • 0
  • 0
Primary Antibodies

AB233178

PE Anti-PD1 antibody [EH12.2H7]

Flow Cytometry - PE Anti-PD1 antibody [EH12.2H7] (AB233178)

  • 0
  • 0
Primary Antibodies

AB89828

Anti-PD1 antibody

Western blot - Anti-PD1 antibody (AB89828)

  • 0
  • 0
Primary Antibodies

AB210291

PE Anti-PD1 antibody [J43.1]

Flow Cytometry - PE Anti-PD1 antibody [J43.1] (AB210291)

  • 0
  • 0
Primary Antibodies

AB246683

violetFluor™ 450 Anti-PD1 antibody [RMP1-30]

Flow Cytometry - violetFluor™ 450 Anti-PD1 antibody [RMP1-30] (AB246683)

  • 0
  • 0
Primary Antibodies

AB210290

Anti-PD1 antibody [J43.1] - Low endotoxin, Azide free

  • 0
  • 0
Primary Antibodies

AB171267

Anti-PD1 antibody [J116] - Low endotoxin, Azide free

Flow Cytometry - Anti-PD1 antibody [J116] - Low endotoxin, Azide free (AB171267)

  • 0
  • 0
Primary Antibodies

AB95789

Anti-PD1 antibody [J43]

Flow Cytometry - Anti-PD1 antibody [J43] (AB95789)

  • 0
  • 0
Primary Antibodies

AB227681

Anti-PD1 antibody [SP269]

20ul selling size|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [SP269] (AB227681)

  • 0
  • 0

Complementary Products

Assay Kits

AB252360

Human PD-1 ELISA Kit

Recombinant|SimpleStep

ELISA - Human PD-1 ELISA Kit (AB252360)

  • 0
  • 0
Primary Antibodies

AB205921

Anti-PD-L1 antibody [28-8]

BOND RX™ Validated|20ul selling size|Recombinant|KO Validated|Advanced Validation|RabMAb

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [28-8] (AB205921)

  • 4
  • 15
Primary Antibodies

AB133616

Anti-CD4 antibody [EPR6855]

BOND RX™ Validated|RabMAb|Recombinant|Lab Essentials|20ul selling size|Advanced Validation

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD4 antibody [EPR6855] (AB133616)

  • 5
  • 19
Primary Antibodies

AB20034

Anti-FOXP3 antibody [236A/E7]

BOND RX™ Validated|Recombinant|Lab Essentials|Advanced Validation

Multiplex immunohistochemistry - Anti-FOXP3 antibody [236A/E7] (AB20034)

  • 4
  • 38
Primary Antibodies

AB237709

Anti-CD8 alpha antibody [CAL66]

BOND RX™ Validated|20ul selling size|RabMAb|Advanced Validation|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD8 alpha antibody [CAL66] (AB237709)

  • 5
  • 2
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/250 - 1/500", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval before commencing with IHC staining protocol.", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "1/100", "FlowCyt-species-notes": "<p><a href='/en-us/products/primary-antibodies/rabbit-igg-monoclonal-epr25a-isotype-control-ab172730'>ab172730</a> - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.</p>", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>" } } }
style
left-column

Product details

Anti-PD1 antibody [EPR4877(2)] (ab137132) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-P .

Anti-PD1 antibody [EPR4877(2)] (ab137132) was first used in a scientific publication in 2014 and has been cited over 101 times in peer reviewed journals. It's performance in IHC in human samples is trusted by the scientific community.

Abcam's high quality manufacturing and validation processes ensure Anti-PD1 antibody [EPR4877(2)] (ab137132) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.

Anti-PD1 antibody [EPR4877(2)] (ab137132) has 5 independent reviews from customers.

Anti-PD1 antibody [EPR4877(2)] (ab137132) specifically detects PD1 (UniProt ID: Q15116; Molecular weight: 29kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL).

Conjugation-ready, carrier free format available for antibody clone EPR4877(2) - ab186928.

Antibody clone EPR4877(2) is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 647, Alexa Fluor® 555, Alexa Fluor® 594, Alexa Fluor® 488, Alexa Fluor® 568, Alexa Fluor® 750 (ab201825, ab275126, ab275349, ab311022, ab313074, ab321110).

PD-1 is an immune checkpoint receptor that, when engaged by its ligands PD-L1 or PD-L2, inhibits T-cell activity, allowing tumors to evade immune detection. Blocking the PD-1 pathway with immune checkpoint inhibitors reactivates T-cells, enhancing the immune system's ability to target and destroy cancer cells.

Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PD1 also known as Programmed Cell Death Protein 1 or PDCD1 is a transmembrane protein that plays a critical role in regulating immune responses. It has a mass of approximately 55 kDa. PD1 is expressed on the surface of T cells B cells and some myeloid cells. PD1’s expression increases upon activation of these immune cells assisting in maintaining peripheral tolerance. Researchers often use PD1 mouse models and chimeric antibodies to explore the function of PD1 for experimental purposes. Antibodies such as anti-PD1 such as EH12.2H7 help in blocking PD1 interaction to study its role further.
Biological function summary

PD1 serves as an inhibitory receptor acting as a checkpoint in the immune system. It becomes part of an immune-suppressive complex when it binds with its ligands PD-L1 or PD-L2 which are expressed on various cell types including some tumor cells. This interaction suppresses the proliferation of T cells and cytokine production contributing to immune homeostasis. By controlling T cell activity PD1 limits autoimmunity but can also reduce the immune system's capability to attack cancer cells.

Pathways

PD1 functions in the immune checkpoint pathway a critical regulatory circuit in immune regulation. The engagement of PD1 with its ligands initiates a cascade that inhibits the function and proliferation of T cells through downstream SHP-2 phosphatase activity. This pathway frequently involves other regulatory proteins like CTLA-4 and is an important mechanism by which the body modulates immune responses. Related pathways often intersect with those involving T cell receptor signaling and contribute to the overall modulation of immune activity.

PD1 has a significant role in cancer and autoimmune disorders. PD1 expression can allow tumors to evade immune surveillance making PD1 a target for cancer therapies such as anti-PD1 antibodies which aim to block PD1 and restore T cell activity. The interaction of PD1 with cancer-related proteins like PD-L1 facilitates tumor immune evasion. In autoimmune disorders PD1’s regulation of immune balance can become dysregulated leading to persistent immune activation and tissue damage. Understanding PD1 and its interaction with proteins such as PD-L1 helps in developing therapeutic strategies for both cancer and autoimmune conditions.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 21276005, PubMed : 31754127, PubMed : 32184441, PubMed : 37208329). Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 (PubMed : 21276005, PubMed : 26602187). Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation (PubMed : 32184441). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2 : following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (PubMed : 32184441).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28951311). The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 28951311). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 22658127, PubMed : 25034862, PubMed : 25399552).
See full target information PDCD1
style
left-column

Publications (138)

Recent publications for all applications. Explore the full list and refine your search

Nature 646:462-473 PubMed40836096

2025

Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy.

Applications

Unspecified application

Species

Unspecified reactive species

Erez N Baruch,Frederico O Gleber-Netto,Priyadharsini Nagarajan,Xiayu Rao,Shamima Akhter,Tuany Eichwald,Tongxin Xie,Mohammad Balood,Adebayo Adewale,Shorook Naara,Hinduja N Sathishkumar,Shajedul Islam,William McCarthy,Brandi J Mattson,Renata Ferrarotto,Michael K Wong,Michael A Davies,Sonali Jindal,Sreyashi Basu,Karine Roversi,Amin Reza Nikpoor,Maryam Ahmadi,Ali Ahmadi,Catherine Harwood,Irene Leigh,Dennis Gong,Paulino Tallón de Lara,Derrick L Tao,Tara M Davidson,Nadim J Ajami,Andrew Futreal,Kunal Rai,Veena Kochat,Micah Castillo,Preethi Gunaratne,Ryan P Goepfert,Sharia D Hernandez,Nikhil I Khushalani,Jing Wang,Stephanie S Watowich,George A Calin,Michael R Migden,Mona Yuan,Naijiang Liu,Yi Ye,William L Hwang,Paola D Vermeer,Nisha J D'Silva,Yuri L Bunimovich,Dan Yaniv,Jared K Burks,Javier Gomez,Patrick M Dougherty,Kenneth Y Tsai,James P Allison,Padmanee Sharma,Jennifer A Wargo,Jeffrey N Myers,Sebastien Talbot,Neil D Gross,Moran Amit

Cancer research and treatment : PubMed40808531

2025

Clinicopathological Significance of Tumor-Infiltrating T Lymphocytes and Macrophages in Primary Large B-Cell Lymphoma of Immune-Privileged Sites.

Applications

Unspecified application

Species

Unspecified reactive species

Jinseong Kim,Deokhoon Kim,Hyungwoo Cho,Dok-Hyun Yoon,Heounjeong Go

Nature 644:1058-1068 PubMed40659786

2025

Microbiota-driven antitumour immunity mediated by dendritic cell migration.

Applications

Unspecified application

Species

Unspecified reactive species

Nina Yi-Tzu Lin,Shota Fukuoka,Shohei Koyama,Daisuke Motooka,Dieter M Tourlousse,Yuko Shigeno,Yuki Matsumoto,Hiroyuki Yamano,Kazutoshi Murotomi,Hideyuki Tamaki,Takuma Irie,Eri Sugiyama,Shogo Kumagai,Kota Itahashi,Tokiyoshi Tanegashima,Kaori Fujimaki,Sachiko Ito,Mariko Shindo,Takahiro Tsuji,Hiroaki Wake,Keisuke Watanabe,Yuka Maeda,Tomohiro Enokida,Makoto Tahara,Riu Yamashita,Takao Fujisawa,Motoo Nomura,Akihito Kawazoe,Koichi Goto,Toshihiko Doi,Kohei Shitara,Hiroyuki Mano,Yuji Sekiguchi,Shota Nakamura,Yoshimi Benno,Hiroyoshi Nishikawa

International journal of molecular sciences 26: PubMed40565313

2025

Immune-Checkpoint Expression in Breast Cancer Patients: Clinicopathological Implications: A Retrospective Case Series Study.

Applications

Unspecified application

Species

Unspecified reactive species

Angel Quiroz-Bolaños,Antonio Quintero-Ramos,Juliana Marisol Godínez-Rubí,Ramon Franco-Topete,Porfirio Gutiérrez González,Bricia M Gutiérrez-Zepeda,Denisse S Becerra-Loaiza,Antonio Topete,Cesar de Loera-Rodriguez,Alicia Del Toro-Arreola,Adrián Daneri-Navarro

Cancer immunology, immunotherapy : CII 74:230 PubMed40445404

2025

Prognostic significance of osteosarcopenia and its effects on immune response in patients with stage II/III gastric cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Yuki Hirase,Takaaki Arigami,Daisuke Matsushita,Masataka Shimonosono,Yusuke Tsuruda,Ken Sasaki,Kenji Baba,Yota Kawasaki,Takao Ohtsuka

Current oncology (Toronto, Ont.) 32: PubMed40422521

2025

The Spatial Proximity of CD8 FoxP3PD-1 Cells to Tumor Cells: A More Accurate Predictor of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Zijuan Hu,Zhihuang Hu,Keji Chen,Huixia Huang,Xinyang Zhong,Yaxian Wang,Jiayu Chen,Xuefeng He,Di Shi,Yupeng Zeng,Jiwei Li,Xiaoyan Zhou,Ping Wei

Clinical and translational medicine 15:e70310 PubMed40268516

2025

Response-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational study.

Applications

Unspecified application

Species

Unspecified reactive species

Rong Shen,Wei-Guo Cao,Li Wang,Ling-Shuang Sheng,Yi-Lun Zhang,Wen Wu,Peng-Peng Xu,Shu Cheng,Meng-Ke Liu,Yan Dong,Yue Wang,Xiang-Qin Weng,Xu-Feng Jiang,Qi Song,Hong-Mei Yi,Lei Li,Sheng Chen,Zi-Xun Yan,Wei-Li Zhao

Communications biology 8:621 PubMed40240529

2025

Breast cancer patient-derived scaffolds enhance the understanding of PD-L1 regulation and T cell cytotoxicity.

Applications

Unspecified application

Species

Unspecified reactive species

Elena Garre,Sara Rhost,Anna Gustafsson,Louis Szeponik,Thais Fenz Araujo,Marianne Quiding-Järbrink,Khalil Helou,Anders Ståhlberg,Göran Landberg

Nature communications 16:2944 PubMed40140675

2025

Spatial mapping of immune cell environments in NF2-related schwannomatosis vestibular schwannoma.

Applications

Unspecified application

Species

Unspecified reactive species

Adam P Jones,Michael J Haley,Miriam H Meadows,Grace E Gregory,Cathal J Hannan,Ana K Simmons,Leoma D Bere,Daniel G Lewis,Pedro Oliveira,Miriam J Smith,Andrew T King,D Gareth R Evans,Pawel Paszek,David Brough,Omar N Pathmanaban,Kevin N Couper

Cancer medicine 14:e70658 PubMed40062505

2025

Radiation-Enhanced AF1q Moves Center Stage as a Key Driver to Favorable Tumor Stage in Rectal Cancer Patients.

Applications

Unspecified application

Species

Unspecified reactive species

Elisabeth S Gruber,Georg Oberhuber,Elisabeth Gurnhofer,Robert Eferl,Gerald Timelthaler,Béla Teleky,D I Dietmar Georg,Joachim Widder,William Tse,Lukas Kenner
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com